Orgenesis Inc (ORGS) Return on Assets ROA from the fourth quarter of 2024 to fourth quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Dec 31 2024 to Dec 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Orgenesis Inc   (ORGS)


Orgenesis Inc 's ROA from the fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Orgenesis Inc 's ROA in the fourth quarter of 2024?
Orgenesis Inc achieved a return on average assets (ROA) of 212.94 % in its fourth quarter of 2024, which is below Orgenesis Inc 's average return on assets, which stands at 214.76%.

ROA has improved compared to 133.97% in the third quarter of 2024, due to net income growth.

However, within the Healthcare sector 6 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2024 quarter, so far to 30, from total ROA ranking in the third quarter of 2024 at 40.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter
Y / Y Total Assets Change -90.72 % 66.36 % 60.28 % -58.08 % -83.91 %
Y / Y Net Income Change 207.66 % - - - 420.68 %
Net Income (TTM) in million 49 35 22 -13 -42
Return On Assets (TTM) 212.94 % 133.97 % 95.14 % -61.56 % -134.8 %
ORGS's Total Ranking # 30 # 40 # 60 # 4483 # 5594
Total Assets (TTM) in million 1 29 31 31 15
Seq. Total Assets Change -95.38 % -4.46 % -1.13 % 112.42 % -17.09 %
Seq. Net Income Change 119.9 % -1.07 % -6.39 % 51.06 % -

ORGS's 5 Years Annual ROA >> Back to ORGS Management Effectiveness >> Compare ORGS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 2
Sector # 7
Overall # 27

Return On Assets Statistics
High Average Low
2124.91 %
214.76 %
-135.52 %
(Feb 28 2013)   (Dec 31 2023)



  News about Orgenesis Inc Return on Assets ROA

Resplendent Triumph Orgenesis ORG-101 CAR-T Therapy Achieves Landmark Success in CD19+ Acute Lymphoblastic Leukemia ...

Orgenesis Heralds Victorious Results: A Triumph in CAR-T Therapy for CD19+ Acute Lymphoblastic Leukemia Esteemed readers of CSIMarket.com ,In a resplendent display of scientific advancement and medical prowess, Orgenesis Inc. an imperious entity in the biotechnology realm, has announced the prodigious outcomes of its real-world study, concentrating on ORG-101, a CAR-T therapy aimed at combating CD19+ Acute Lymphoblastic Leukemia (ALL). The culmination of this scrutinized study has yielded results that shall undoubtedly engrave Orgenesis’ name in the annals of medical triumphs.The ORG-101, a meticulously engineered CD19 CAR-T therapy, has attained an illustrious complete response (CR) of 82% among adult participants, ascending to an even more distinguished 93% in the pediatric cohort. This praiseworthy achievement is further augmented by the auspicious incidence of severe Cytokine Release Syndrome (CRS), which stood at a meager 2% in adult patients and a trifling 6% in the younger demographic. Such statistics manifest not only the efficacy but the remarkable safety and tolerability of ORG-101 in real-world conditions.



Financial Statements
Orgenesis Inc 's Assets $ 1 million ORGS's Balance sheet
Orgenesis Inc 's Income $ 20 million Quarterly ORGS's Income Statement
ORGS's Income by Division See ORGS's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -90.72 % -83.91 % 50.64 % -22.19 % -14.08 %
Total Assets in million 1 15 90 60 77
Y / Y Net Income Change -24.5 % 433.47 % -32.62 % 3019 % -97.78 %
Net Income in million 49 65 12 18 1
Annual Return On Assets 3627.91 % 445.87 % 13.45 % 30.06 % 0.75 %

ORGS's 5 Years Annual ROA >> Back to ORGS Management Effectiveness >> Compare ORGS ROA to its Competitors



Comment on ORGS's ROA in the fiscal year ending 2024
Despite deterioration in net income of -24.5 % to $49.01 million, Orgenesis Inc 's ROA improved in the fiscal year2024 to 3627.91 % compared to previous year, as the value of ORGS's assets decline even faster to $1.35 million, from $1.35 a year before.


More Return On Assets Ratios
ORGS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ORGS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ORGS's Competitors
Subscribers only: Roa for Orgenesis Inc 's Suppliers
Subscribers only: Return On Assets for ORGS's Customers

You may also want to know
ORGS's Roi ORGS's Inventory Turnover Ratio ORGS's Growth Rates ORGS's Dividend Comparisons
ORGS's Profitability Ratios ORGS's Asset Turnover Ratio ORGS's Dividend Growth
ORGS's Roe ORGS's Valuation Ratios ORGS's Financial Strength Ratios ORGS's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2024, within Healthcare Sector ROA
Vystar Corporation  416.91 %
Ir med Inc   337.60 %
Traws Pharma inc   268.33 %
Capforce Inc   214.54 %
Orgenesis Inc   211.87 %
AnTix Holdings, Inc.  194.68 %
Camp4 Therapeutics Corporation  146.34 %
Inspira Technologies Oxy B H N Ltd  136.96 %
Alumis inc   124.51 %
Polypid Ltd  115.08 %
Pavmed Inc   82.47 %
Oak Woods Acquisition Corp  80.22 %
Addex Therapeutics Ltd  66.08 %
Longduoduo Co Ltd  62.80 %
Tao Synergies Inc   58.36 %
Sbc Medical Group Holdings Incorporated  56.18 %
Agios Pharmaceuticals Inc   53.07 %
Earth Science Tech Inc   52.61 %
Interpace Biosciences Inc   51.47 %
Gridai Technologies Corp  51.03 %
Adma Biologics Inc   49.22 %

Date modified: 2026-06-22T14:32:46+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.